A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease
Conditions: Celiac Disease; Coeliac Disease Interventions: Drug: KAN-101; Drug: Placebo Sponsors: Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA; Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 21, 2023 Category: Research Source Type: clinical trials
No-biopsy Approach in Celiac Disease: Cut-off Points for IgA Anti-tissue Transglutaminase Assays
Condition: Celiac Disease Intervention: Sponsors: Instituto de Investigación Hospital Universitario La Paz; Hospital Universitari Mutua Terrassa; Hospital Sant Joan de Deu; Hospital Universitario Ramon y Cajal; Hospital Universitario Lucus Augusti; Hospital Universitario Fundación Jiménez Díaz; Instituto de Investigación Sanitaria Hospital Clínico San Carlos Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 9, 2023 Category: Research Source Type: clinical trials
